TY  - CHAP
M1  - Book, Section
TI  - Nephritic Spectrum Glomerular Diseases
A1  - Dirkx, Tonja C.
A1  - Woodell, Tyler B.
A2  - Papadakis, Maxine A.
A2  - McPhee, Stephen J.
A2  - Rabow, Michael W.
A2  - McQuaid, Kenneth R.
PY  - 2022
T2  - Current Medical Diagnosis & Treatment 2022
AB  - Key  Clinical  Updates  in  Nephritic  Spectrum  Glomerular  DiseasesPrior  trials  suggested  that  corticosteroids  reduced  proteinuria  when  administered  to  patients  with  GFR  >  50  mL/min/1.73  m2  and  persistent  proteinuria  >  1  g.  However,  more  recent  data  failed  to  demonstrate  slowing  of  GFR  loss  with  corticosteroid  therapy  compared  with  use  of  ACE  inhibitor  or  ARB  alone;  enthusiasm  for  glucocorticoid  therapy  therefore  has  waned.Trials  using  the  complement  inhibitor  avacopan  in  place  of  glucocorticoids  in  cyclophosphamide-  or  rituximab-based  regimens  are  ongoing  and  appear  promising.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/18
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1184183309
ER  -